IBDEI0XX ; ; 20-MAY-2015
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;OCT 15, 2014
 Q:'DIFQR(358.3)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,99) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.3,16748,0)
 ;;=461.9^^92^941^60
 ;;^UTILITY(U,$J,358.3,16748,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,16748,1,4,0)
 ;;=4^461.9
 ;;^UTILITY(U,$J,358.3,16748,1,5,0)
 ;;=5^Sinusitis, Acute
 ;;^UTILITY(U,$J,358.3,16748,2)
 ;;=^259080
 ;;^UTILITY(U,$J,358.3,16749,0)
 ;;=473.9^^92^941^59
 ;;^UTILITY(U,$J,358.3,16749,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,16749,1,4,0)
 ;;=4^473.9
 ;;^UTILITY(U,$J,358.3,16749,1,5,0)
 ;;=5^Sinusitis Chronic
 ;;^UTILITY(U,$J,358.3,16749,2)
 ;;=^123985
 ;;^UTILITY(U,$J,358.3,16750,0)
 ;;=091.0^^92^941^65
 ;;^UTILITY(U,$J,358.3,16750,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,16750,1,4,0)
 ;;=4^091.0
 ;;^UTILITY(U,$J,358.3,16750,1,5,0)
 ;;=5^Syphilis,Primary Genital
 ;;^UTILITY(U,$J,358.3,16750,2)
 ;;=^50581
 ;;^UTILITY(U,$J,358.3,16751,0)
 ;;=097.0^^92^941^63
 ;;^UTILITY(U,$J,358.3,16751,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,16751,1,4,0)
 ;;=4^097.0
 ;;^UTILITY(U,$J,358.3,16751,1,5,0)
 ;;=5^Syphilis,Latent
 ;;^UTILITY(U,$J,358.3,16751,2)
 ;;=^266781
 ;;^UTILITY(U,$J,358.3,16752,0)
 ;;=094.9^^92^941^64
 ;;^UTILITY(U,$J,358.3,16752,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,16752,1,4,0)
 ;;=4^094.9
 ;;^UTILITY(U,$J,358.3,16752,1,5,0)
 ;;=5^Syphilis,Neurosyphilis
 ;;^UTILITY(U,$J,358.3,16752,2)
 ;;=^83026
 ;;^UTILITY(U,$J,358.3,16753,0)
 ;;=097.9^^92^941^62
 ;;^UTILITY(U,$J,358.3,16753,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,16753,1,4,0)
 ;;=4^097.9
 ;;^UTILITY(U,$J,358.3,16753,1,5,0)
 ;;=5^Syphilis NOS
 ;;^UTILITY(U,$J,358.3,16753,2)
 ;;=^116808
 ;;^UTILITY(U,$J,358.3,16754,0)
 ;;=463.^^92^941^66
 ;;^UTILITY(U,$J,358.3,16754,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,16754,1,4,0)
 ;;=4^463.
 ;;^UTILITY(U,$J,358.3,16754,1,5,0)
 ;;=5^Tonsillitis
 ;;^UTILITY(U,$J,358.3,16754,2)
 ;;=^2695
 ;;^UTILITY(U,$J,358.3,16755,0)
 ;;=130.9^^92^941^67
 ;;^UTILITY(U,$J,358.3,16755,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,16755,1,4,0)
 ;;=4^130.9
 ;;^UTILITY(U,$J,358.3,16755,1,5,0)
 ;;=5^Toxoplasmosis NOS
 ;;^UTILITY(U,$J,358.3,16755,2)
 ;;=^120695
 ;;^UTILITY(U,$J,358.3,16756,0)
 ;;=011.90^^92^941^68
 ;;^UTILITY(U,$J,358.3,16756,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,16756,1,4,0)
 ;;=4^011.90
 ;;^UTILITY(U,$J,358.3,16756,1,5,0)
 ;;=5^Tuberculosis
 ;;^UTILITY(U,$J,358.3,16756,2)
 ;;=^122756
 ;;^UTILITY(U,$J,358.3,16757,0)
 ;;=614.2^^92^941^69
 ;;^UTILITY(U,$J,358.3,16757,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,16757,1,4,0)
 ;;=4^614.2
 ;;^UTILITY(U,$J,358.3,16757,1,5,0)
 ;;=5^Tubo-Ovarian Abcess
 ;;^UTILITY(U,$J,358.3,16757,2)
 ;;=^107806
 ;;^UTILITY(U,$J,358.3,16758,0)
 ;;=788.7^^92^941^72
 ;;^UTILITY(U,$J,358.3,16758,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,16758,1,4,0)
 ;;=4^788.7
 ;;^UTILITY(U,$J,358.3,16758,1,5,0)
 ;;=5^Urethral Discharge
 ;;^UTILITY(U,$J,358.3,16758,2)
 ;;=^265872
 ;;^UTILITY(U,$J,358.3,16759,0)
 ;;=131.02^^92^941^73
 ;;^UTILITY(U,$J,358.3,16759,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,16759,1,4,0)
 ;;=4^131.02
 ;;^UTILITY(U,$J,358.3,16759,1,5,0)
 ;;=5^Urethritis, Trichomonal
 ;;^UTILITY(U,$J,358.3,16759,2)
 ;;=^266955
 ;;^UTILITY(U,$J,358.3,16760,0)
 ;;=597.80^^92^941^74
 ;;^UTILITY(U,$J,358.3,16760,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,16760,1,4,0)
 ;;=4^597.80
 ;;^UTILITY(U,$J,358.3,16760,1,5,0)
 ;;=5^Urethritis, Unsp
 ;;^UTILITY(U,$J,358.3,16760,2)
 ;;=^124214
 ;;^UTILITY(U,$J,358.3,16761,0)
 ;;=079.99^^92^941^78
 ;;^UTILITY(U,$J,358.3,16761,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,16761,1,4,0)
 ;;=4^079.99
 ;;^UTILITY(U,$J,358.3,16761,1,5,0)
 ;;=5^Viral Syndrome
 ;;^UTILITY(U,$J,358.3,16761,2)
 ;;=^295798
